Durvalumab, with or without tremelimumab, plus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer: 3-year overall survival update from CASPIAN
- L. Paz-Ares
- , Y. Chen
- , N. Reinmuth
- , K. Hotta
- , D. Trukhin
- , G. Statsenko
- , M. J. Hochmair
- , M. Özgüroğlu
- , J. H. Ji
- , M. C. Garassino
- , O. Voitko
- , A. Poltoratskiy
- , E. Musso
- , L. Havel
- , I. Bondarenko
- , G. Losonczy
- , N. Conev
- , H. Mann
- , T. B. Dalvi
- , H. Jiang
- Hospital Universitario 12 de Octubre
- Cancer & Hematology Centers of Western Michigan
- Munich-Gauting
- Okayama University
- Odessa Regional Oncological Dispensary
- Omsk Regional Cancer Center
- Krankenhaus Nord
- Istanbul University - Cerrahpaşa
- Sungkyunkwan University
- IRCCS Fondazione Istituto Nazionale per lo studio e la cura dei tumori - Milano
- The University of Chicago
- Kyiv City Clinical Oncological Centre
- Russian Ministry of Health
- AO Ospedali Riuniti PO Vincenzo Cervello
- Charles University
- Zaporizhia Medical Academy of Post-Gradate Education Ministry of Health of Ukraine
- Semmelweis University
- Clinic of Medical Oncology
- AstraZeneca
- University of California at Los Angeles
Research output: Contribution to journal › Article › peer-review
293
Link opens in a new tab
Scopus
citations